Scientific Sessions 2026 Daily News: Monday, Nov. 9

7 #ScientificSessions26 ScientificSessions.org was 57; 27% were female; almost 50% were in NYHA III. The co-primary outcomes were time to the first occurrence of a composite of all-cause mortality, allcause hospitalization and stroke, and quality of life was assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) at three months. Secondary confirmatory outcomes were 6MWD and qualityadjusted utility values based on the European Quality of Life Questionnaire (EQ-5D-5L). The first co-primary outcome occurred in 364 patients (21.0%) in the intervention group and 401 (22.8%) in the control group (HR=0.90; 95% CI: [0.78, 1.04], p=0.15). The second co-primary outcome, MLHFQ score, improved more with yoga-based rehabilitation (between-group difference in change from baseline -8.06; 95% CI: [-8.87, -7.24], p<0.001); lower scores indicate better quality of life. Similar improvements were observed in the secondary confirmatory outcome, 6MWD (between-group difference in change from baseline 25.5; 95% CI: [20.8, 30.3], p<0.001), and qualityadjusted utility values based on the EQ-5D-5L, with a between-group difference in change from baseline (0.05; 95% CI: [0.03, 0.06], p<0.001). Overall, although yoga-based rehabilitation did not significantly reduce all-cause mortality, all-cause hospitalization and stroke, it improved quality of life, increased 6MWD and quality-adjusted utility-value at three months, with the difference persisting through 24 months. Dorairaj Prabhakaran, MD “Reducing hospitalizations and improving quality of life with heart failure is much needed in countries like India, where an estimated 500,000 to 1.8 million new heart failure cases are diagnosed each year,” said principal investigator Dorairaj Prabhakaran, MD, executive director of the Center for Chronic Disease Control in New Delhi, India. He noted that future research needs to focus on scaling yoga interventions and evaluating their effectiveness across diverse international settings. MI or nonfatal stroke was 0.81 (95% CI: [0.68, 0.98], p=0.03), for allcause mortality, nonfatal MI/stroke or hospitalization for unstable angina/heart failure 0.84 (95% CI: [1.24, 0.97], p=0.02) and for stroke 0.73 (95% CI: [0.56, 0.94]). Other secondary cardiovascular outcomes were not statistically significant. The intensive blood pressure control group had worse renal outcomes, HR 1.76 (95% CI: [1.21, 2.50]). There were similar rates of serious adverse events, orthostatic hypotension, or injuries. Berwanger noted that the increase in kidney-related events, primarily reductions in kidney function, underlines the need for individualized treatment and careful monitoring for all patients. “Many clinicians have worried that lowering blood pressure too far after an ischemic stroke could reduce blood flow to the brain and trigger another event,” he said. “In clinically stable patients, we saw fewer ischemic strokes, not more, with a target below 120 mmHg. It is also meaningful that we showed this benefit in a population that has been underrepresented in previous trials of intensive blood pressure lowering.” OPTIMAL-STROKE was published simultaneously in the New England Journal of Medicine. STROKE continued from page 5 Be sure to visit the Poster Hall In the Science & Technology Hall Find out how Lp(a) impacts your patients Novartis Pharmaceuticals Corporation supports Driving Awareness and Shared Decision-Making Around Lp(a) 2026. © 2026 American Heart Association, Inc., 501(c)(3) not-for-profit. All rights reserved. Lifelong Learning is a trademark of the AHA. Unauthorized use prohibited. WF650001 10/26 Paid Advertisement Lp(a) Toolkit for Healthcare Professionals High levels of plasma lipoprotein(a) (Lp(a)) are independently associated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of myocardial infarction, peripheral arterial disease, and stroke. Learn more in this toolkit for healthcare professionals. Lp(a): A Survey for Healthcare Professionals We invite you to take part in a brief survey designed to assess your knowledge of Lp(a) and help us understand your practice. Your responses will help the American Heart Association shape future educational activities that drive further awareness of Lp(a) screening and overall ASCVD risk management.

RkJQdWJsaXNoZXIy MjI2NjI=